By: Olga Torres
Through these tests, 324 tumor genes will be extensively analyzed to identify clinically relevant alterations, which will allow the physician to access a clear and detailed report to support clinical decision making, thus speeding up diagnosis, treatment, and patient management times according to need.
Under the “Precision Medicine Alliance. One genome, one team”, this test will be available free of charge to 131 patients in Central America and the Caribbean. In this way, it will be possible to determine whether there are possible actionable alterations for which treatments or combinations of treatments are available.
The pilot plan for this first year is part of a patient support program between the three pharmaceutical companies to cover the performance of 131 tests in those patients who meet the inclusion criteria and are in Costa Rica, Honduras, El Salvador, Guatemala, Panama, Dominican Republic, and the Caribbean, within the private health system. The total number of tests will be distributed among the countries, as requests from physicians arise.
Lung cancer has an average of two million deaths each year; timely diagnosis will reduce this number.
We congratulate our customers for always being at the forefront of innovation not only in research and development but also in the relentless pursuit of improving the lives of every patient.